Brilinta's North America Anomaly Stymies AstraZeneca, Worries Analysts
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite ticagrelor's resounding victory over Plavix in the global PLATO study, a subanalysis showing the antiplatelet drug didn't work on North Americans raises questions about how FDA will see the data.
You may also be interested in...
Brilinta Approval Shows AstraZeneca's Success With Aspirin Theory, But Can It Change The Market?
FDA appears to have come around to the "aspirin hypothesis" offered by AstraZeneca PLC to explain poor results for North American patients who took the blood-thinner Brilinta, though labeling takes a somewhat cautious approach that reflects initial concerns about that explanation.
Brilinta Approval Shows AstraZeneca's Success With Aspirin Theory, But Can It Change The Market?
FDA appears to have come around to the "aspirin hypothesis" offered by AstraZeneca PLC to explain poor results for North American patients who took the blood-thinner Brilinta, though labeling takes a somewhat cautious approach that reflects initial concerns about that explanation.
AstraZeneca's Brilinta Approved With Aspirin Warning
Anti-platelet ticagrelor carries a boxed warning that concomitant aspirin dose must be limited to 100 mg/day, a departure for U.S. prescribers accustomed to high-dose aspirin therapy.